Telix Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
First Patient Enrolled in ProstACT TARGET Study 2022-09-27 05:00
Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data 2022-09-21 07:51
Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment 2022-08-24 05:56
Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant 2022-08-08 07:55
Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging 2022-08-02 06:54
BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging 2022-07-27 20:30
Telix Reports Second Quarter 2022 Financial Results 2022-07-21 08:34
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment 2022-07-11 08:26
Kevin Richardson appointed as CEO, Telix Americas 2022-07-11 08:13
Telix and Invicro Advance AI Partnership 2022-06-14 19:00
Telix and Invicro Advance AI Partnership 2022-06-14 14:21
Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network 2022-06-13 19:11
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment 2022-06-10 19:00
Telix to Present at Jefferies Healthcare Conference 2022-06-07 19:00
Telix Showcasing Innovation in Theranostics at SNMMI 2022-06-07 05:00
Illuccix® Granted Transitional Pass-Through Payment Status 2022-05-31 19:00
Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S. 2022-05-30 08:02
First Patient Dosed in Phase II Renal Cancer Theranostics Study 2022-05-05 05:00
Telix Further Strengthens European Distribution Network for Illuccix 2022-04-22 07:10
First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent 2022-04-14 19:00
1 3 4 5 6 7